Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026)

Cogent Biosciences' Non-Current Assets history spans 10 years, with the latest figure at $25.2 million for Q1 2026.

  • Quarterly Non-Current Assets fell 18.47% to $25.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $111.0 million through Mar 2026, down 32.67% year-over-year, with the annual reading at $27.3 million for FY2025, 13.28% down from the prior year.
  • Non-Current Assets came in at $25.2 million for Q1 2026, down from $27.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $69.5 million in Q3 2023 to a low of $12.1 million in Q1 2022.
  • The 5-year median for Non-Current Assets is $35.1 million (2022), against an average of $37.4 million.
  • Year-over-year, Non-Current Assets skyrocketed 393.68% in 2022 and then tumbled 50.29% in 2025.
  • Cogent Biosciences' Non-Current Assets stood at $35.8 million in 2022, then increased by 19.03% to $42.7 million in 2023, then fell by 26.34% to $31.4 million in 2024, then dropped by 13.28% to $27.3 million in 2025, then decreased by 7.52% to $25.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Non-Current Assets are $25.2 million (Q1 2026), $27.3 million (Q4 2025), and $28.7 million (Q3 2025).